Development of an AlphaLISA assay to quantify serum core-fucosylated E-cadherin as a metastatic lung adenocarcinoma biomarker

Journal of Proteomics

Volumn 75, Issue 13, 2012, Pages 3963-3976

  Wen, Chu Ling ^a   Chen, Kuan Yu ^b   Chen, Chih Ta ^a   Chuang, Jiing Guang ^a   Yang, Pan Chyr ^b   Chow, Lu Ping ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

2D DIGE; AlphaLISA; E cadherin; Lectin affinity column; Lung adenocarcinoma; Serum glycoproteomics

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3C; COMPLEMENT COMPONENT C4A; CONCANAVALIN A; FIBRINOGEN; HAPTOGLOBIN; LECTIN; PROTEIN PRECURSOR; SERUM AMYLOID P; UVOMORULIN;

ADULT; AFFINITY CHROMATOGRAPHY; AGED; ARTICLE; ASSAY; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; FUCOSYLATION; FUCOSYLATION INDEX; HIGH THROUGHPUT SCREENING; HUMAN; LIQUID CHROMATOGRAPHY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MASS SPECTROMETRY; METASTASIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REPRODUCIBILITY; STAINING; SURVIVAL RATE; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; WESTERN BLOTTING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CADHERINS; CARCINOMA, NON-SMALL-CELL LUNG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

ALEURIA AURANTIA;

EID: 84862667123     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.05.015     Document Type: Article

References (51)

1. Infante M.V., Pedersen J.H. Screening for lung cancer: are we there yet?. Curr Opin Pulm Med 2010, 16:301-306.
2. Herbst R.S., Heymach J.V., Lippman S.M. Lung cancer. N Engl J Med 2008, 359:1367-1380.
3. Reddy C., Chilla D., Boltax J. Lung cancer screening: a review of available data and current guidelines. Hosp Pract (Minneap) 2011, 39:107-112.
4. Lababede O., Meziane M., Rice T. Seventh edition of the cancer staging manual and stage grouping of lung cancer: quick reference chart and diagrams. Chest 2011, 139:183-189.
5. Travis W.D., Brambilla E., Noguchi M., Nicholson A.G., Geisinger K., Yatabe Y., et al. International association for the study of lung cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc 2011, 8:381-385.
6. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
7. Charloux A., Quoix E., Wolkove N., Small D., Pauli G., Kreisman H. The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. Int J Epidemiol 1997, 26:14-23.
8. Liaw Y.P., Huang Y.C., Lien G.W. Patterns of lung cancer mortality in 23 countries: application of the age-period-cohort model. BMC Public Health 2005, 5:22.
9. Little A.G., Gay E.G., Gaspar L.E., Stewart A.K. National survey of non-small cell lung cancer in the United States: epidemiology, pathology and patterns of care. Lung Cancer 2007, 57:253-260.
10. Lopes Pegna A., Picozzi G. Lung cancer screening update. Curr Opin PulmMed 2009, 15:327-333.
11. Bolukbas S., Eberlein M., Schirren J. Management of lung nodules detected by volume CT scanning. NEngl J Med 2010, 362:757-758. author reply 8-9.
12. Cedres S., Nunez I., Longo M., Martinez P., Checa E., Torrejon D., et al. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC). Clin Lung Cancer 2011, 12:172-179.
13. Chee J., Naran A., Misso N.L., Thompson P.J., Bhoola K.D. Expression of tissue and plasma kallikreins and kinin B1 and B2 receptors in lung cancer. Biol Chem 2008, 389:1225-1233.
14. Wojcik E., Kulpa J.K., Sas-Korczynska B., Korzeniowski S., Jakubowicz J. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer. Anticancer Res 2008, 28:3027-3033.
15. Drake P.M., Cho W., Li B., Prakobphol A., Johansen E., Anderson N.L., et al. Sweetening the pot: adding glycosylation to the biomarker discovery equation. Clin Chem 2010, 56:223-236.
16. Kim Y.S., Yoo H.S., Ko J.H. Implication of aberrant glycosylation in cancer and use of lectin for cancer biomarker discovery. Protein Pept Lett 2009, 16:499-507.
17. Stamey T.A., Yang N., Hay A.R., McNeal J.E., Freiha F.S., Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987, 317:909-916.
18. Gadducci A., Cosio S., Carpi A., Nicolini A., Genazzani A.R. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother 2004, 58:24-38.
19. Fujino N., Haga Y., Sakamoto K., Egami H., Kimura M., Nishimura R., et al. Clinical evaluation of an immunoradiometric assay for CA15-3 antigen associated with human mammary carcinomas: comparison with carcinoembryonic antigen. Jpn J Clin Oncol 1986, 16:335-346.
20. Tan E., Gouvas N., Nicholls R.J., Ziprin P., Xynos E., Tekkis P.P. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg Oncol 2009, 18:15-24.
21. Narimatsu H., Sawaki H., Kuno A., Kaji H., Ito H., Ikehara Y. A strategy for discovery of cancer glyco-biomarkers in serum using newly developed technologies for glycoproteomics. FEBS J 2010, 277:95-105.
22. Kobayashi M., Morita T. Significant expression patterns of lewis X-related antigens as a prognostic predictor of low-stage renal cell carcinomas. Anticancer Res 2010, 30:593-599.
23. Bafna S., Kaur S., Batra S.K. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene 2010, 29:2893-2904.
24. Zhao J., Patwa T.H., Lubman D.M., Simeone D.M. Protein biomarkers in cancer: natural glycoprotein microarray approaches. Curr Opin Mol Ther 2008, 10:602-610.
25. Ullman E.F., Kirakossian H., Singh S., Wu Z.P., Irvin B.R., Pease J.S., et al. Luminescent oxygen channeling immunoassay: measurement of particle binding kinetics by chemiluminescence. Proc Natl Acad Sci U S A 1994, 91:5426-5430.
26. Cauchon E., Liu S., Percival M.D., Rowland S.E., Xu D., Binkert C., et al. Development of a homogeneous immunoassay for the detection of angiotensin I in plasma using AlphaLISA acceptor beads technology. Anal Biochem 2009, 388:134-139.
27. Chang C.F., Pan J.F., Lin C.N., Wu I.L., Wong C.H., Lin C.H. Rapid characterization of sugar-binding specificity by in-solution proximity binding with photosensitizers. Glycobiology 2011, 21:895-902.
28. Jung K., Cho W., Regnier F.E. Glycoproteomics of plasma based on narrow selectivity lectin affinity chromatography. J Proteome Res 2009, 8:643-650.
29. Anderson L. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J Physiol 2005, 563:23-60.
30. Hanash S.M., Pitteri S.J., Faca V.M. Mining the plasma proteome for cancer biomarkers. Nature 2008, 452:571-579.
31. Zhang Q., Faca V., Hanash S. Mining the plasma proteome for disease applications across seven logs of protein abundance. J Proteome Res 2011, 10:46-50.
32. Guzman N.A., Blanc T., Phillips T.M. Immunoaffinity capillary electrophoresis as a powerful strategy for the quantification of low-abundance biomarkers, drugs, and metabolites in biological matrices. Electrophoresis 2008, 29:3259-3278.
33. Zeng X., Hood B.L., Sun M., Conrads T.P., Day R.S., Weissfeld J.L., et al. Lung cancer serum biomarker discovery using glycoprotein capture and liquid chromatography mass spectrometry. J Proteome Res 2010, 9:6440-6449.
34. Mehta A., Block T.M. Fucosylated glycoproteins as markers of liver disease. Dis Markers 2008, 25:259-265.
35. Shiraki K., Takase K., Tameda Y., Hamada M., Kosaka Y., Nakano T. A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology 1995, 22:802-807.
36. Matsuda M., Asakawa M., Amemiya H., Fujii H. Lens culinaris agglutinin-reactive fraction of AFP is a useful prognostic biomarker for survival after repeat hepatic resection for HCC. J Gastroenterol Hepatol 2011, 26:731-738.
37. Oka H., Saito A., Ito K., Kumada T., Satomura S., Kasugai H., et al. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein. J Gastroenterol Hepatol 2001, 16:1378-1383.
38. Marrero J.A., Romano P.R., Nikolaeva O., Steel L., Mehta A., Fimmel C.J., et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol 2005, 43:1007-1012.
39. Comunale M.A., Lowman M., Long R.E., Krakover J., Philip R., Seeholzer S., et al. Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J Proteome Res 2006, 5:308-315.
40. Comunale M.A., Wang M., Hafner J., Krakover J., Rodemich L., Kopenhaver B., et al. Identification and development of fucosylated glycoproteins as biomarkers of primary hepatocellular carcinoma. J Proteome Res 2009, 8:595-602.
41. Tsai H.Y., Boonyapranai K., Sriyam S., Yu C.J., Wu S.W., Khoo K.H., et al. Glycoproteomics analysis to identify a glycoform on haptoglobin associated with lung cancer. Proteomics 2011, 11:2162-2170.
42. Matsumura K., Higashida K., Ishida H., Hata Y., Yamamoto K., Shigeta M., et al. Carbohydrate binding specificity of a fucose-specific lectin from Aspergillus oryzae: a novel probe for core fucose. J Biol Chem 2007, 282:15700-15708.
43. Ullman E.F., Kirakossian H., Switchenko A.C., Ishkanian J., Ericson M., Wartchow C.A., et al. Luminescent oxygen channeling assay (LOCI): sensitive, broadly applicable homogeneous immunoassay method. Clin Chem 1996, 42:1518-1526.
44. Charalabopoulos K., Gogali A., Kostoula O.K., Constantopoulos S.H. Cadherin superfamily of adhesion molecules in primary lung cancer. Exp Oncol 2004, 26:256-260.
45. Makrilia N., Kollias A., Manolopoulos L., Syrigos K. Cell adhesion molecules: role and clinical significance in cancer. Cancer Invest 2009, 27:1023-1037.
46. De Wever O., Derycke L., Hendrix A., De Meerleer G., Godeau F., Depypere H., et al. Soluble cadherins as cancer biomarkers. Clin Exp Metastasis 2007, 24:685-697.
47. Nawrocki-Raby B., Gilles C., Polette M., Bruyneel E., Laronze J.Y., Bonnet N., et al. Upregulation of MMPs by soluble E-cadherin in human lung tumor cells. Int J Cancer 2003, 105:790-795.
48. Symowicz J., Adley B.P., Gleason K.J., Johnson J.J., Ghosh S., Fishman D.A., et al. Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res 2007, 67:2030-2039.
49. Zhao Y., Sato Y., Isaji T., Fukuda T., Matsumoto A., Miyoshi E., et al. Branched N-glycans regulate the biological functions of integrins and cadherins. FEBS J 2008, 275:1939-1948.
50. Liwosz A., Lei T., Kukuruzinska M.A. N-glycosylation affects the molecular organization and stability of E-cadherin junctions. J Biol Chem 2006, 281:23138-23149.
51. Stanczak A., Stec R., Bodnar L., Olszewski W., Cichowicz M., Kozlowski W., et al. Prognostic significance of Wnt-1, beta-catenin and E-cadherin expression in advanced colorectal carcinoma. Pathol Oncol Res 2011, 17:955-963.